Total cancer care moffit cancer center
GO
 

Johnathan Mark Lancaster, MD, PhD

Where You Are:
Johnathan Mark Lancaster, MD, PhD

Associate Member

"Dr. Lancaster's research is focused on the molecular genetic etiology of ovarian cancer development, progression and response to therapy."

Office  (888) 860-2778

Education And Training
  • PhD, University of Wales, 2005
  • Fellow, Duke University Medical Center, 2003 - Gynecologic Oncology
  • Resident, Duke University Medical Center, 2000 - Obstetrics and Gynecology
  • MD, University of Wales, 1997
  • Resident, Cambridge University, Addenbrooke's Hospital, 1994 - Obstetrics and Gynecology
  • Intern, University of Wales, 1993 - General Internship
  • MBBCh, University of Wales, 1992
  • BSc, University of Wales, 1991 - Pharmacology


The primary focus of research in Dr. Lancaster’s laboratory relates to the characterization of the molecular determinants of ovarian cancer development, response to therapy and clinical outcome, with overarching goals to develop personalized medicine strategies for women with advanced stage epithelial ovarian cancer. Dr. Lancaster and colleagues explored the genome-wide changes that underlie ovarian cancer response to therapy and developed a series of gene expression-based biomarkers associated with clinical phenotypes. Specifically, they developed a series of genomic profiles that are predictive of response to platinum, taxanes, topotecan and doxorubicin.  These signatures are now subject to prospective observational validation in a 4-year NCI R33-funded study.  Additionally, Dr. Lancaster and colleagues have taken advantage of gene array technology to characterize the genome-wide expression changes that drive ovarian cancer chemoresistance. They have identified discrete pathways that can be targeted to increase chemotherapy-induced apoptosis. They focused on characterization of one such pathway (BCL2 antagonist of cell death/BAD-apoptosis) as a biomarker of chemo-response and clinical outcome; identifying a 48-gene expression signature that is associated with ovarian cancer response to platinum-based therapy, and with disease-free/overall survival from ovarian, breast, colon, and brain cancers.

  • Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res. 2013 May;18(19):5489-5498. Pubmedid: 22837181. Pmcid: PMC3463759.
  • Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-2018. Pubmedid: 23467907.
  • Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013 Apr;130(1):19-24. Pubmedid: 23623830.
  • Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Mar;208(6):501.e1-501.e7. Pubmedid: 23507546.
  • Pal T, Lee JH, Besharat A, Thompson Z, Monteiro A, Phelan C, Lancaster J, Metcalfe K, Sellers T, Vadaparampil S, Narod S. Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet. 2013 Feb. Pubmedid: 23438721.
  • Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013 Jan. Pubmedid: 23353819.
  • Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012 Dec;287(42):34970-34978. Pubmedid: 22927443. Pmcid: PMC3471722.
  • Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Aug;23(1):35-42. Pubmedid: 22355465. Pmcid: PMC3280065.
  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer. 2012 Aug;106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.
  • Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Aug;41(1):179-188. Pubmedid: 22552627.
  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002.
  • Martino MA, George JG, Chen CC, Galic V, Kapoor R, Murray KC, Shubella J, Riker E, Lancaster JM, Hoffman MS. Preoperative Enoxaparin Is Safe to Use in Major Gynecologic Surgery for Prophylaxis of Venous Thromboembolism: A Retrospective Cohort Study. Int J Gynecol Cancer. 2012 May;22(4):681-685. Pubmedid: 22343972.
  • Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2012 Feb;30(6):678. Pubmedid: 22451975.
  • Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez-Bosquet J, Iversen E, Jim H, McLaughlin J, Menon U, Narod SA, Phelan CM, Ramus SJ, Risch H, Song H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuck A, Pharoah PD, Schildkraut JM, Goode EL, Sellers TA. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2012 Feb;20(8):1793-1797. Pubmedid: 21636674. Pmcid: PMC3153581.
  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan;124(1):119-124. Pubmedid: 22032837.
  • Sun J, He H, Xiong Y, Lu S, Shen J, Cheng A, Chang WC, Hou MF, Lancaster JM, Kim M, Yang S. Fascin protein is critical for transforming growth factor ? protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem. 2011 Nov;286(45):38865-38875. Pubmedid: 21914811. Pmcid: PMC3234711.
  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct;17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.
  • Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011 Sep;71(11):3896-3903. Pubmedid: 21482675. Pmcid: PMC3107389.
  • Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, Stockwell H, Dagne G, Iversen E, Risch H, Barnholtz-Sloan J, Cunningham JM, Vierkant RA, Fridley BL, Sutphen R, McLaughlin J, Narod SA, Goode EL, Schildkraut JM, Fenstermacher D, Phelan CM, Sellers TA. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(6):1131-1145. Pubmedid: 21447778. Pmcid: PMC3111851.
  • Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control. 2011 Jan;18(1):8-15. Pubmedid: 21273975.
  • Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug;203(2):158.e1-158.40. Pubmedid: 20444440.
  • Pidala J, Bloom GC, Enkemann S, Eschrich S, Lancaster J, Anasetti C. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Jun;16(6):729-738. Pubmedid: 19922809.
  • Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC. Inherited determinants of ovarian cancer survival. Clin Cancer Res. 2010 Apr;16(3):995-1007. Pubmedid: 20103664. Pmcid: PMC2818685.
  • Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 2009 Dec;19(9):1564-1569. Pubmedid: 19955938.
  • Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, Keefe DL, Albrecht TL. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009 Dec;27(35):5952-5957. Pubmedid: 19826115.
  • Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol. 2009 Nov;100(6):511-514. Pubmedid: 19697350.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 Apr;113(2):249-255. Pubmedid: 19237188.
  • Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009 Apr;15(7):2448-2455. Pubmedid: 19318476. Pmcid: PMC3050629.
  • Lu K, Kauff N, Powell CB, Chen LM, Cass I, Lancaster JM. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009 Apr;113(4):957-966. Pubmedid: 19305347.
  • Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila). 2009 Feb;2(2):114-121. Pubmedid: 19174584.
  • Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep;6(8):766-794. Pubmedid: 18926089.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug;110(2):206-215. Pubmedid: 18499237.
  • Lancaster J, Bethan Powell C, Kauff N, Cass I, Chen L, Lu K, Mutch D, Berchuck A, Karlan B, Herzog T. Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-162. Pubmedid: 17950381.
  • Martino MA, Williamson E, Rajaram L, Lancaster JM, Hoffman MS, Maxwell GL, Clarke-Pearson DL. Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis. Gynecol Oncol. 2007 Sep;106(3):439-445. Pubmedid: 17599396.
  • Indermaur M, Shoup B, Tebes S, Lancaster J. The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy. Am J Obstet Gynecol. 2007 May;196(5):e40-e42. Pubmedid: 17466676.
  • Nasir A, Boulware D, Kaiser H, Lancaster J, Coppola D, Smith P, Hakam A, Siegel S, Bodey B. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007 Jan;21(1):35-43. Pubmedid: 17354612.
  • Morgan RJ J, Alvarez R, Armstrong D, Chen L, Copeland L, Fowler J, Gaffney D, Gershenson D, Greer B, Johnston C, Lancaster J, Lele S, MatulonisU, Ozols R, Remmenga S, Sabbatini P, Soper J, Teng N. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Oct;4(9):912-939. Pubmedid: 17020669.
  • Lancaster J, Dressman H, Clarke J, Sayer R, Martino M, Cragun J, Henriott A, Gray J, Sutphen R, Elahi A, Whitaker R, West M, Marks J, NevinsJR, Berchuck A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer. 2006 Sep;16(5):1733-1745. Pubmedid: 17009964.
  • Lancaster J, Sayer R, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg D, Marks J, Berchuck A. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006 Jul;16(4):1529-1535. Pubmedid: 16884361.
  • Martino MA, Borges E, Williamson E, Siegfried S, Cantor AB, Lancaster J, Roberts WS, Hoffman MS. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006 Mar;107(3):666-671. Pubmedid: 16507939.
  • Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D, Joshi M, Harpole D, Lancaster J, Berchuck A, Olson JA J, Marks J, Dressman H, West M, Nevins J. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan;439(7074):353-357. Pubmedid: 16273092.
  • Berchuck A, Iversen E, Lancaster J, Pittman J, Luo J, Lee P, Murphy S, Dressman H, Febbo P, West M, Nevins J, Marks J. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005 May;11(10):3686-3696. Pubmedid: 15897565.
  • Sayer R, Lancaster J, Pittman J, Gray J, Whitaker R, Marks J, Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelialovarian cancer. Gynecol Oncol. 2005 Feb;96(2):355-361. Pubmedid: 15661221.
  • Li L, Chen L, Goldgof D, George F, Chen Z, Rao A, Cragun J, Sutphen R, Lancaster J. Integration of clinical information and gene expression profiles for prediction of chemo-response for ovarian cancer. Conf Proc IEEE Eng Med Biol Soc. 2005;5:4818-4821. Pubmedid: 17281320.
  • Chen L, Li L, Goldgof D, George F, Chen Z, Rao A, Cragun J, Sutphen R, Lancaster J. Improving Reliability of Response Prediction to Platinum-Based Therapy by AdaBoost and Multiple Classifiers. Conf Proc IEEE Eng Med Biol Soc. 2005;5:4822-4825. Pubmedid: 17281321.
  • Lancaster J, Sayer R. Reply to dursun et Al. Gynecol Oncol. 2005;99(2):523-524. Pubmedid: 16139350.
  • Berchuck A, Iversen E, Lancaster J, Dressman H, West M, Nevins J, Marks J. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol. 2004;190(4):910-923. Pubmedid: 15118612.
  • Lancaster J, Dressman H, Whitaker R, Habrilesky L, Gray J, Marks J, Nevins J, Berchuck A. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig. 2004;11(1):51-59. Pubmedid: 14706684.
  • Lancaster J, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res. 2003;9(2):762-766. Pubmedid: 12576447.
  • Havrilesky L, Alvarez A, Sayer R, Lancaster J, Soper J, Berchuck A, Clarke-Pearson D, Rodriguez G, Carney M. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2003;88(1):51-57. Pubmedid: 12504627.
  • Lancaster J, Calingaert B, Wenham R, Marks J, Moorman P, Halabi S, Bentley R, Berchuck A, Schildkraut J. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev. 2003;12(3):226-227. Pubmedid: 12646513.
  • Wenham R, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, LancasterJM, Schildkraut J, Marks J, Berchuck A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovariancancer. J Soc Gynecol Investig. 2003;10:381-387. Pubmedid: 12969782.
  • Wenham R, Lancaster J, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16(4):483-497. Pubmedid: 12413930.
  • Carney M, Lancaster J, Ford C, Tsodikov A, Wiggins C. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol. 2002;84(1):36-42. Pubmedid: 11748973.
  • Dixon D, Flake G, Moore A, He H, Haseman J, Risinger J, Lancaster J, Berchuck A, Barrett J, Robboy S. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441(1):53-62. Pubmedid: 12111201.
  • Alvarez A, Lambers A, Lancaster J, Maxwell G, Gumbs C, Berchuck A, Futreal P. Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol. 2001;82(1):94-98. Pubmedid: 11426968.
  • Lancaster J, Risinger J, Carney M, Barrett J, Berchuck A. Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol. 2001;184(6):1051-1053. Pubmedid: 11349153.
  • Lancaster J, Carney M, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D, France E, Wiseman R, Harper P, Futreal P. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. Br J Cancer. 1998 Dec;78(11):1417-1420. Pubmedid: 9836472 .
  • Berchuck A, Heron K, Carney M, Lancaster J, Fraser E, Vinson V, Deffenbaugh A, Miron A, Marks J, Futreal P, Frank T. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998 Oct;4(10):2433-2437. Pubmedid: 9796975 .
  • Carney M, Maxwell G, Lancaster J, Gumbs C, Marks J, Berchuck A, Futreal P. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J Soc Gynecol Investig. 1998 Sep;5(5):281-285. Pubmedid: 9773405 .
  • Lancaster J, Berchuck A, Carney M, Wiseman R, Taylor J. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer. 1998 Jul;78(2):277-277. Pubmedid: 9683307 .
  • Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G, Bergerheim U. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene. 1998 Jan;16(4):481-487. Pubmedid: 9484837 .
  • Lancaster J, Berchuck A, Futreal P, Wiseman R. Dideoxy fingerprinting assay for BRCA1 mutation analysis. Mol Carcinog. 1997 Jul;19(3):176-179. Pubmedid: 9254884 .
  • Lancaster JM, Carney ME, Futreal PA. BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer. Medscape Womens Health. 1997 Feb;2(2):7-. Pubmedid: 9746681.
  • Lancaster J, Brownlee H, Bell D, Futreal P, Marks J, Berchuck A, WisemanRW, Taylor J. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog. 1996 Nov;17(3):160-162. Pubmedid: 8944076 .
  • Berchuck A, Cirisano F, Lancaster J, Schildkraut J, Wiseman R, Futreal A, Marks J. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-746. Pubmedid: 8828444 .
  • Lancaster J, Wooster R, Mangion J, Phelan C, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman R, Berchuck A, Iglehart J, Marks J, Ashworth A, Stratton M, Futreal P. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun;13(2):238-240. Pubmedid: 8640235 .
  • Phelan C, Lancaster J, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher M, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod S, Futreal P. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genetics. 1996 May;13(1):120-122. Pubmedid: 8673090 .
  • Lancaster J, Cochran C, Brownlee H, Evans A, Berchuck A, Futreal P, Wiseman R. Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. J Natl Cancer Inst. 1996 Apr;88(8):552-554. Pubmedid: 8606385 .
  • Lancaster J, Wiseman R, Berchuck A. An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol. 1996 Feb;87(2):306-309. Pubmedid: 8559544 .
  • Jacobs IJ, Lancaster JM. The molecular genetics of sporadic and familial epithelial cancer. Int J Gynecol Cancer. 1996;6:337-355.
  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec;378(6559):789-792. Pubmedid: 8524414 .
  • Lancaster J, Brownlee H, Wiseman R, Taylor J. p53 polymorphism in ovarian and bladder cancer. Lancet. 1995 Jul;346(8968):182-182. Pubmedid: 7603246 .
  • Lancaster J, Davies J. Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice. Experientia. 1992 Aug;48(8):751-753. Pubmedid: 1516682 .
  • Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Krüger Kjaer S, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Kiong Lim B, Lin J, Lissowska J, Lu KH, Lubi?ski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Anne Rossing ...

Office: (888) 860-2778

BACK TO RESEARCH PAGE
 
TOOLS:   Font Size
 |  Site Map  |  Privacy Policy  |  Terms and Conditions  |  Staff Login